Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

Chiara Massa , Thomas Karn , Karsten Weber , Andreas Schneeweiss , Claus Hanusch , Jens Uwe Blohmer , Dirk-Michael Zahm , Christian Jackisch , Marion van Mackelenbergh , Jörg Thomalla , Frederik Marmé , Jens Huober , Volkmar Müller , Christian Schem , Anja Müller , Elmar Stickeler , Katharina Biehl , Peter A. Fasching , Michael Untch , Sibylle Loibl , Carsten Denkert , Barbara Seliger

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (4) : e1617

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (4) : e1617 DOI: 10.1002/ctm2.1617
LETTER TO THE JOURNAL

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

Author information +
History +
PDF

Cite this article

Download citation ▾
Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk-Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger. Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clinical and Translational Medicine, 2024, 14(4): e1617 DOI:10.1002/ctm2.1617

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Isaacs J, Anders C, McArthur H, Force J. Biomarkers of immune checkpoint blockade response in triple-negative breast cancer. Curr Treat Options Oncol. 2021;22(5):38.

[2]

Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279-1288.

[3]

Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062.

[4]

Massa C, Karn T, Denkert C, et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020;8(2).

[5]

Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609.

[6]

Kumar D, Mishra A, Lisok A, et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021;118(37).

[7]

Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al. Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021.

[8]

Saura-Esteller J, de Jong M, King LA, et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front Immunol. 2022;13:915837.

[9]

Holmen Olofsson G, Pedersen SR, Aehnlich P, Svane IM, Idorn M. The capacity of CD4(+) Vgamma9Vdelta2 T cells to kill cancer cells correlates with co-expression of CD56. Cytotherapy. 2021;23(7):582-589.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

145

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/